US 12,152,076 B2
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
Matthew Bernett, Monrovia, CA (US); Gregory Moore, Azusa, CA (US); John Desjarlais, Pasadena, CA (US); Michael Hedvat, Encino, CA (US); Christine Bonzon, Los Angeles, CA (US); Alex Nisthal, Monrovia, CA (US); and Umesh Muchhal, Monrovia, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Monrovia, CA (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,799.
Application 17/696,799 is a continuation of application No. 16/184,895, filed on Nov. 8, 2018, granted, now 11,312,770.
Claims priority of provisional application 62/658,227, filed on Apr. 16, 2018.
Claims priority of provisional application 62/598,938, filed on Dec. 14, 2017.
Claims priority of provisional application 62/583,438, filed on Nov. 8, 2017.
Prior Publication US 2022/0204624 A1, Jun. 30, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2896 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 11 Claims
 
1. A Programmed Cell Death Protein 1 (PD-1) binding domain comprising a variable heavy domain, and a variable light domain selected from the following:
a) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:41291, a vhCDR2 having the amino acid sequence of SEQ ID NO:41292, and a vhCDR3 having the amino acid sequence of SEQ ID NO:41293, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:41296, a vlCDR2 having the amino acid sequence of SEQ ID NO:41297, and a vlCDR3 having the amino acid sequence of SEQ ID NO:41298;
b) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:41231, a vhCDR2 having the amino acid sequence of SEQ ID NO:41232, and a vhCDR3 having the amino acid sequence of SEQ ID NO:41233, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO: 41236, a vlCDR2 having the amino acid sequence of SEQ ID NO: 41237, and a vlCDR3 having the amino acid sequence of SEQ ID NO: 41238;
c) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:41241, a vhCDR2 having the amino acid sequence of SEQ ID NO:41242, and a vhCDR3 having the amino acid sequence of SEQ ID NO: 41243, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:41246, a vlCDR2 having the amino acid sequence of SEQ ID NO: 41247, and a vlCDR3 having the amino acid sequence of SEQ ID NO:41248;
d) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:41361, a vhCDR2 having the amino acid sequence of SEQ ID NO:41362, and a vhCDR3 having the amino acid sequence of SEQ ID NO:41363, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:41366, a vlCDR2 having the amino acid sequence of SEQ ID NO:41367, and a vlCDR3 having the amino acid sequence of SEQ ID NO:41368;
e) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:42506, a vhCDR2 having the amino acid sequence of SEQ ID NO: 42507, and a vhDR3 having the amino acid sequence of SEQ ID NO: 42508, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:42511, a vlCDR2 having the amino acid sequence of SEQ ID NO:42512, and a vlCDR3 having the amino acid sequence of SEQ ID NO:42513;
f) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:43286, a vhCDR2 having the amino acid sequence of SEQ ID NO:43287, and a vhCDR3 having the amino acid sequence of SEQ ID NO:43288, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:43291, a vlCDR2 having the amino acid sequence of SEQ ID NO:43292, and a vlCDR3 having the amino acid sequence of SEQ ID NO:43293; and
g) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:43176, a vhCDR2 having the amino acid sequence of SEQ ID NO:43177, and a vhCDR3 having the amino acid sequence of SEQ ID NO: 43178, and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:43181, a vlCDR2 having the amino acid sequence of SEQ ID NO:43182, and a vlCDR3 having the amino acid sequence of SEQ ID NO:43183.